Researchers of a study presented at the American Association for Cancer Research Annual Meeting 2024 revealed promising outcomes for patients with recurrent or persistent microsatellite-stable endometrial cancer treated with a combination of mirvetuximab soravtansine-gynx and pembrolizumab. The study employed a single-arm phase 2 trial design, showing that 37.5% of patients achieved objective responses, with some experiencing prolonged progression-free survival. The combination therapy demonstrated notable activity, particularly in patients who had received multiple prior lines of treatment, suggesting potential benefits of combining antibody-drug conjugates with immunotherapies for this patient population.
The study’s success prompts further exploration into molecular changes within tumors and features of the tumor microenvironment that may predict response or resistance to the therapy. The researchers aim to enhance the duration of response for patients who do respond, underscoring the importance of continued investigation into novel treatment approaches for microsatellite-stable endometrial cancer.
Reference: The ASCO Post Staff. Mirvetuximab Soravtansine Plus Pembrolizumab in Patients With Endometrial Cancer Subtype. The ASCO Post. Published April 8, 2024. Accessed April 23, 2024. https://ascopost.com/news/april-2024/mirvetuximab-soravtansine-plus-pembrolizumab-in-patients-with-endometrial-cancer-subtype/
